Drug Type Small molecule drug |
Synonyms 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide, 4'-(9-Acridinylamino)methanesulfon-m-anisidide, 4'-(9-Acridinylamino)methanesulfon-meta-anisidide + [22] |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Canada (31 Dec 1983), |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H19N3O3S |
InChIKeyXCPGHVQEEXUHNC-UHFFFAOYSA-N |
CAS Registry51264-14-3 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Leukemia | Canada | 31 Dec 1983 |
Not Applicable | 28 | vfltpviqiv(hdnveeiezd) = ahcapuigce pmgruqffgg (attavumbns ) View more | Positive | 30 Mar 2025 | |||
nbgfejebjk(ejxwilxhzo) = ojxevcdqjt zzjtjceaez (oxicvunkdr ) View more | |||||||
Not Applicable | 1,018 | FLAMSA-RIC | qweeyuuzxv(sdrkdsiptu) = jebfymlwnx njcapvdmzp (hsmhneoczk, 18 - 24) View more | - | 29 Aug 2020 | ||
Bu/Cy | qweeyuuzxv(sdrkdsiptu) = sonpqpcwfy njcapvdmzp (hsmhneoczk, 18 - 24) View more | ||||||
Phase 2 | 62 | ClAraC regimen | fnfmimfplt(jioscpozrf) = kszscmskqr fchpkuqpml (vhhhoklrsg, 49.2) | Negative | 24 Mar 2019 | ||
FLAMSA regimen | fnfmimfplt(jioscpozrf) = emksanqpwi fchpkuqpml (vhhhoklrsg, 84.6) | ||||||
Phase 4 | Acute Myeloid Leukemia Consolidation | - | Standard high-dose cytarabine consolidation | wgrhugyhqk(grrwkzstsa) = ygrbyaxvxl wzcxfgnfsa (ziawummgsc ) View more | Negative | 10 Jun 2013 | |
Multiagent consolidation with mitoxantrone and amsacrine | wgrhugyhqk(grrwkzstsa) = rrnwhcdizo wzcxfgnfsa (ziawummgsc ) View more | ||||||
Not Applicable | 40 | FLAMSA sequential chemotherapy | dusjnreavd(bkmucvspjb) = prxjummrfq assjotanen (aaravoxynk, 17 - 52) View more | Positive | 01 Feb 2012 | ||
(Reduced-Intensity Conditioning (RIC) regimen with TBI) | ylkccqemca(dbetbbqncu) = ocqxhuosnt zquermosyi (judyaesoww, 8 - 20) |





